Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioLineRx Announces Publication of Pre-Clinical Results Demonstrating Efficacy of BL-7010

Published: Thursday, August 23, 2012
Last Updated: Thursday, August 23, 2012
Bookmark and Share
Data showing reduction of gluten toxicity published in leading medical journal Gastroenterology.

BioLineRx has announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient’s body).

The research was published in the February edition of Gastroenterology.

The findings indicate that BL-7010 (previously called P(HEMA-co-SS)) reduces digestion of wheat gluten, thereby decreasing its toxicity.

In addition, BL-7010 attenuates the immune response to gluten in rodents and prevents gluten-induced pathological damage to the small intestine.

BL-7010 was not absorbed systemically, indicating its safety as a gluten-neutralizing substance.

These data demonstrate that BL-7010 has the potential to be an effective adjunctive therapy to the gluten-free diet, to prevent or reduce gluten-induced disorders in humans.

"Celiac disease is a highly prevalent autoimmune disease, which occurs in genetically predisposed individuals who are exposed to gluten, a protein found in wheat, barley and rye," said Dr. Kinneret Savitsky, CEO of BioLineRx.

Dr. Savitsky continued, "Currently, there is no cure or pharmacological treatment for the disease, and treatment consists of adhering to a life-long, strict, gluten-free diet, which is extremely hard to maintain and is not effective in all cases. BL-7010 may attenuate the immune response to gluten and reduce subsequent damage to the small intestine. This compound, therefore, has the potential to be an effective adjunctive pharmacological therapy to improve the quality of life for millions of celiac disease patients.”

BL-7010 is a novel, non-absorbable, orally available polymer intended for the treatment of celiac disease and gluten sensitivity. It has a high affinity for gliadins, the immunogenic peptides present in gluten that cause celiac disease.

BL-7010 acts locally in the gastrointestinal tract, masking gliadins and then undergoing excretion. This significantly reduces the immune response triggered by gluten.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioLineRx Announces Positive Preclinical Results for Leukemia Treatment
BioLineRx announced today positive pre-clinical results for BL-8040 in a third indication - as a treatment for chronic myeloid leukemia.
Tuesday, February 25, 2014
BioLineRx In-Licenses Second Oral Hepatitis C Treatment
Advantages of BL-8030 include high specificity, improved resistance profile, reduced toxicity and potentially reduced drug-drug interactions.
Thursday, May 24, 2012
BioLineRx Receives Approval for Commencing Phase II Clinical Trial of BL-7040
Results expected by end of 2012.
Tuesday, March 06, 2012
BioLineRx Announces Positive Preliminary Results from the Phase I/II Trial of BL-1040
Trial results show the BL-1040’s efficacy in preventing cardiac remodeling and preserving cardiac function.
Friday, June 05, 2009
BioLineRx Receives Approval to Complete Phase 1/2 Clinical Trials of BL-1040
The pilot Phase 1/2 multi-center open label study is designed to assess the safety and preliminary efficacy of BL-1040 in up to 30 patients.
Tuesday, January 13, 2009
Scientific News
Rates of Nonmedical Prescription Opioid Use Disorder Double in 10 Years
Researchers at NIH have found that the nonmedical use of prescription opioids has more than doubled among adults in the United States from 2001-2002 to 2012-2013.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
‘Human-on-a-Chip’ Could Replace Animal Testing
Researchers are developing a “human-on-a-chip,” a miniature external replication of the human body, integrating biology and engineering with a combination of microfluidics and multi-electrode arrays.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
‘Missing Tooth’ Hydrogels Handle Hard-to-Deliver Drugs
Rice University’s custom hydrogel traps water-avoiding molecules for slow delivery.
Copper is Key in Burning Fat
Berkeley Lab scientist says results could provide new target for obesity research.
Better Animal Model to Improve HIV Vaccine Development
Penn study identifies a new tool to produce better HIV vaccine designs.
Identifying Side-Effects At Early Stages Of Drug Development
An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline (GSK).
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!